Tumor Gangliosides Inhibit the Tumor-Specific Immune Response

Robert McKallip, Ruixiang Li and Stephan Ladisch

*J Immunol* 1999; 163:3718-3726; 
http://www.jimmunol.org/content/163/7/3718

**References** This article cites 53 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/163/7/3718.full#ref-list-1

**Subscription** Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions** Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Tumor Gangliosides Inhibit the Tumor-Specific Immune Response

Robert McKallip, Ruixiang Li, and Stephan Ladisch

Tumor gangliosides are highly immunosuppressive membrane glycosphingolipids that are shed into the tumor cell microenvironment. We directly tested the impact of shed gangliosides on the in vivo antitumor immune response in a syngeneic fully autochthonous system (FBL-3 erythroleukemia cells, C57BL/6 mice, and highly purified FBL-3 cell gangliosides). The major FBL-3 ganglioside was identified as G_{M1b} by mass spectrometry. Substantial ganglioside shedding (90 pmol/10^8 cells/h), a requisite for their inhibition of the immune function of tumor-infiltrating leukocytes, was detected. Immunosuppression by FBL-3 gangliosides was potent; 5–20 µM inhibited the tumor-specific secondary proliferative response (80–100%) and suppressed the generation of tumor-specific CTLs (97% reduction of FBL-3 cell lysis at an E:T ratio of 100:1). In vivo, coinjection of 10 nmol of FBL-3 gangliosides with a primary FBL-3 cell immunization led to a reduced response to a secondary challenge (the increase in the draining popliteal lymph node mass, cell number, and lymphocyte thymidine incorporation were lowered by 70, 69, and 72%, respectively). Coinjection of gangliosides with a secondary tumor challenge led to a 61, 74, and 42% reduction of the increase in lymph node mass, cell number, and thymidine uptake and a 63–74% inhibition of the increase of draining lymph node T cells (CD3^+), B cells (CD19^+), and dendritic cells/macrophages (Mac-3^+). Overall, the clear conclusion that tumor-derived gangliosides inhibit syngeneic antitumor immune responses implicates these molecules as a potent factor in promoting tumor formation and progression.

efficient antitumor immune response. With an autotoxicous system (C57BL/6 mice, syngeneic FBL-3 cells, and highly purified FBL-3 gangliosides), the metabolism (synthesis and shedding) and tumor-specific inhibition of the immune response in vitro and in vivo by the tumor gangliosides was demonstrated. This is the crux of the concept that gangliosides enhance tumor formation by an immunological mechanism. These results provide direct evidence that tumor gangliosides are highly effective inhibitors of the syngeneic antitumor immune response, thereby establishing ganglioside metabolism as an active factor in the process of tumor formation.

Materials and Methods

Tumor cells

FBL-3, a Friend virus-induced erythroleukemia of B6 origin, was kindly provided by Dr. Philip Greenberg. B78H1 melanoma, a variant of B16 melanoma, was kindly provided by Dr. Hyam Levitsky. Both cell lines were maintained in vitro by serial passage in RPMI 1640 medium supplemented with 10% FCS, 1% nonessential amino acids, sodium pyruvate, L-glutamine, penicillin 50 U/ml, streptomycin 50 μg/ml, and 10 mM HEPES buffer (BioWhittaker, Walkersville, MD).

Mice

Female 5–7 wk old C57BL/6 mice (H-2b Thy-1.2), to which the FBL-3 and B78H1 tumor cell lines are syngeneic, were obtained from Harlan Sprague Dawley.

Ganglioside isolation

The cellular gangliosides were isolated from FBL-3 tumor cells which were pelleted, lyophilized, and extracted twice with chloroform-methanol (1:1). The total lipid extract was taken to dryness. Gangliosides were purified by partitioning the dried total lipids in diisopropylether/1-butanol/0.1% aqueous NaCl (24). The lyophilized final aqueous phase was dissolved in a small volume of water, after which Sephadex G-50 gel exclusion chromatography was used to remove salt and low m.w. impurities from the ganglioside fraction. Gangliosides were quantified as nanomols of lipid-bound sialic acid by a modified colorimetric resorcinol assay (25). Analysis of gangliosides was performed using 10–20 cm precoated Silica Gel 60 high performance TLC plates. The plates were developed in chloroform-methanol, 0.25% aqueous CaCl22H2O (60:40:9). Gangliosides were visualized as purple bands with resorcinol-HCl (26).

High performance liquid chromatographic purification of gangliosides

To obtain highly purified tumor cell gangliosides for the immunological studies, in a final step the gangliosides were purified by normal phase HPLC. Briefly, ~800 nmol lipid-bound sialic acid (LBSA) of FBL-3 cell gangliosides in 100 μl HPLC water were chromatographed with a PerkinElmer (Norwalk, CT) HPLC system, on a LiChrosorb-NH2 column (250 mm long, 10 mm inside diameter, Merck, Germany). The separation was conducted at ambient temperature with a solvent gradient program described by Gazzotti et al. (27). The eluting solvent system was composed of acetonitrile-5 mM Sorenson’s phosphate buffer (83:17), pH 5.6 (solvent A), and acetonitrile-20 mM Sorenson’s phosphate buffer (1:1), pH 5.6 (solvent B). The gradient elution program of 80 min, at a flow rate of 6.25 ml/min, was as follows: 100% of solvent A for 7 min, then a linear gradient from 100% solvent A to solvent A-solvent B (66:34) over 53 min, and then a linear gradient from solvent A-solvent B (66:34) to solvent A-solvent B (36:64) over 20 min. The elution profile was monitored by flow-through detection of UV absorbance at 215 nm. The isolated gangliosides were lyophilized, dissolved in a small volume of distilled water, desalted by Sephadex G-50 gel exclusion chromatography, and lyophilized.

Mass spectrometric analysis

The carbohydrate structure of gangliosides was characterized by negative-ion fast atom bombardment mass spectrometry (FAB-MS). Ceramide structures were elucidated by negative ion FAB collisionally activated dissociation tandem MS (FAB CAD-MS/MS) without prior derivatization using lithium salts. Approximately 1 μl of ganglioside-methanol solution was mixed with 2 μl of triethanolamine (matrix) on the FAB probe tip. Ions were formed by bombardment with a 6 keV beam of xenon atoms in a JEOL HX-110 double-focusing mass spectrometer. For analysis of the ceramide structure by FAB CAD-MS/MS, the [CerO]− fragment ion was selected as the precursor ion. Helium was used as the collision gas, and the helium pressure was adjusted to reduce the abundance of the precursor by 75%. A JEOL DA-500 data system generated the linked scans (28).

Ganglioside shedding

FBL-3 tumor cells were metabolically labeled by culture for 48 h in RPMI 1640 medium containing 10 μCi each of n-[1,14C]glucosamine hydrochloride and n-[1,14C]glactose, after which the cells were washed three times in RPMI medium and resuspended at 2.0 × 10⁶ cells/ml in 25 cm² tissue culture flasks. The supernatant and the cells from the same flask were harvested 24 h after the cells were resuspended. The gangliosides present in the cells and in the supernatant were then purified by previously described methods (24). The radiolabeled gangliosides were quantified by β-scintillation counting of the ganglioside-associated radioactivity, and equal aliquots of radiolabeled gangliosides were qualitatively analyzed by high performance TLC (HPTLC) autoradiography (29) with radiolabeled rat brain gangliosides as standards.

Proliferative responses

Mice were immunized by injecting 10⁶ γ-irradiated (10,000 rad) FBL-3 tumor cells in 100 μl PBS i.p. twice at 2-wk intervals (23). The splenocytes were removed from these mice for use in the immunological studies 2 wk after the second injection. Single-cell suspensions of splenocytes were prepared with a laboratory homogenizer (Stomacher, Tekmar, Cincinnati, OH). Contaminating erythrocytes were lysed by resuspending the splenocytes in 5 ml lysing buffer, ACK (BioWhittaker) for 1 min and then washing three times in HB104 medium. After the third wash, the splenocytes were adjusted to 4 × 10⁶ cells/ml in HB104 medium containing 2% FCS and 1% HEPES buffer. This suspension was aliquoted (25 μl) into 96-well A/2 flat-bottom plates. FBL-3 cell gangliosides in 10 μl HB104 medium were added to each well to achieve a final concentration of 0–20 μM. Finally, the cultures were stimulated by addition of 10⁵ irradiated (10,000 rad) syngeneic FBL-3 tumor cells per well. The splenocyte proliferative response was determined 4 days later by adding 0.5 μCi [3H]thymidine (DuPont NEN, Wilmington, DE) to each well for 4 h. [3H]Thymidine uptake was determined by β-scintillation counting. The possibility that the gangliosides were directly toxic to the cells was addressed by determining the number and viability of the splenocytes present at the end of the culture period by trypan blue dye exclusion.

CTL response

Splenocytes (4 × 10⁶ cells/well) from mice immunized against FBL-3 tumor cells were prepared as described above and then cultured in the presence or absence of 20 μM FBL-3 gangliosides in 24-well plates in a final volume of 2 ml for 4 h before restimulation with 4 × 10⁶ γ-irradiated (10,000 rad) FBL-3 tumor cells. The splenocytes were harvested 4 days later and washed three times in HB104 medium to remove unbound gangliosides. The number of splenocytes added was adjusted to achieve the desired E:T ratios and aliquoted (100 μl) to 96 round-bottom plates. Tumor targets were labeled by incubating 1 × 10⁶ cell/ml in 100 μCi sodium [51Cr]chromate (DuPont NEN) for 1 h in RPMI medium containing 10% FCS. The tumor target cells were then washed three times in HB104 medium, adjusted to 10³ cells/ml, and added (5 × 10⁵ cells/50μl/well) to 96-well round-bottom plates. Lysis of the [51Cr]labeled tumor cells was assessed in a standard 4-h chromium release assay (22). [51Cr]labeled EL-4 tumor cells were used as nonspecific control targets. Supernatants were harvested via the Skatron supernatant collection system (Skatron, Sterling, VA). Spontaneous release of label was measured in parallel wells containing target but not effector cells. Maximum release of label was quantified by addition of 50 μl of 1% Triton X-100 to wells containing target cells alone. Samples were counted in a gamma counter (Cobra II, Hewlett Packard, Meriden, CT). Percent lysis was determined by the formula lysis (%) = ([experimental release−spontaneous release] / [total release−spontaneous release]) × 100.

In vivo primary immune response

To assess the effects of gangliosides on the primary antitumor immune response, naïve C57BL/6 mice were immunized by injecting 10⁴ irradiated (10,000 rad) FBL-3 tumor cells in the presence or absence of 10 nmol FBL-3 gangliosides s.c. into their left rear footpads. Two weeks later, the effect of gangliosides on the primary immunization was assessed by determining the response to a secondary tumor challenge measured with a modified version of the popliteal lymph node (PLN) assay (30, 31). Here, mice were rechallenged by injecting them in their left rear footpad with 10³ irradiated (10,000 rad) FBL-3 tumor cells in 50 μl PBS. The immune
response was measured 5 days later by determining the changes in PLN mass, cell number, and [3H]thymidine incorporation, and comparing them with those of unstimulated lymph nodes isolated from the right rear footpad. The cell number was determined after preparing a single-cell suspension of the lymph nodes with a laboratory homogenizer. The lymph node cell suspensions were adjusted to 10^6/ml in RPMI medium containing 10% FCS, and 100 μl were added to triplicate wells in a 96-well flat-bottom plate, pulsed for 18 h with 0.5 μCi [3H]thymidine, and harvested, and [3H]thymidine uptake was determined by β-scintillation counting.

In vivo secondary immune response

Mice were immunized by injecting 10^7 γ-irradiated (10,000 rad) FBL-3 tumor cells in 100 μl PBS i.p. twice at 2-wk intervals (23) and were used for the immunological studies 2 wk after the second injection. The immunized mice received a secondary challenge by injecting them in their left rear footpad with 2.5 × 10^6 irradiated (10,000 rad) FBL-3 tumor cells in 50 μl PBS, admixed with or without 10 nmol of purified FBL-3 tumor cell gangliosides. As a positive control of inhibition, immunized mice were rear footpad with 2.5 × 10^6 irradiated (10,000 rad) FBL-3 tumor cells in 50 μl PBS, admixed with or without 10 nmol of purified FBL-3 tumor cell gangliosides. As a positive control of inhibition, immunized mice were injected into their left footpad with irradiated FBL-3 tumor cells and concomitantly received cyclosporin, 24 mg/kg i.p. daily (32). As a control for specificity of the response, other mice received 2.5 × 10^6 irradiated unirradiated (B7/1H1) tumor cells. Five days after the secondary challenge, the immune response was determined by aseptically removing the draining lymph nodes and quantifying the increase in lymph node mass, cell number, and lymphocyte DNA synthesis compared with those of unstimulated lymph nodes isolated from the right rear footpad, as described above.

Flow cytometric analysis

Cells (5 × 10^5) isolated from the PLNs of C57BL/6 mice were resuspended in cold PBS-0.5% BSA and incubated with fluorescently labeled mAb. The following mAb (PharMingen, San Diego, CA) were used: PE-conjugated hamster IgG isotype standard (anti-keyhole limpet hemocyanin); PE-conjugated anti-CD8; PE-conjugated anti-CD69; PE-conjugated anti-CD25; PE-conjugated anti-CD69; FITC-conjugated anti-CD3; FITC-conjugated anti-CD4; FITC-conjugated anti-CD19; and FITC-conjugated anti-Mac-3. The cells were stained with the mAbs for 30 min on ice, washed twice in PBS-0.5% BSA, and analyzed with a FACStar™ flow cytometer (Becton Dickinson, Mountain View, CA).

Statistical analysis

Student’s unpaired t test (two-tailed) was used to determine the significance of differences between experimental and control data.

Results

Identification of the major FBL-3 ganglioside as G_M1b

FBL-3 gangliosides were isolated (24), quantified (25), and initially analyzed by HPTLC (27). FBL-3 tumor cells contained ~12 nmol gangliosides/10^6 cells. HPTLC analysis of the FBL-3 ganglioside migration pattern (Fig. 1) revealed the FBL-3 ganglioside fraction to contain one major ganglioside doublet. It migrated with HPTLC mobility between that of the human brain ganglioside standards G_M1 and G_D1a, similar to the migration of a ganglioside observed previously in several other mouse tumors and identified as G_M1b (28, 29).

To determine the molecular structure, the HPLC-purified FBL-3 gangliosides were characterized by negative ion FAB-MS analysis. The ganglioside preparation contained two species corresponding to the two bands of the doublet seen by HPTLC and represented by [M – H]^- ions at m/z 1516 and 1626 (Table I). They correspond to two molecular species of the ganglioside G_M1b. Fig. 2 shows the negative-ion mass spectrum of one of the molecular species of G_M1b. The peak at m/z 1626 represents the molecular ion, [M – H]^-. In addition, there are peaks in the mass spectrum that resulted from the loss of N-acetylgalactosaminic acid, galactose, N-acetylgalactosamine and a second galactose. Specifically, the molecular ion [M – H]^- at m/z 1626 yielded the peak at m/z 1335.6 by the loss of N-acetylgalactosaminic acid, and the peak at m/z 1173.6 by the loss of N-acetylgalactosaminic acid and galactose. The loss of N-acetylgalactosaminic acid, galactose, and N-acetylgalactosamine gave the peak at m/z 970.8, whereas the loss of N-acetylgalactosaminic acid, galactose, N-acetylgalactosamine, and a second galactose resulted in the peak at m/z 808.7. The corresponding [CerO]^- was also detected, at m/z 646.6.

The ceramide structures of the FBL-3 ganglioside were further examined by FAB CAD-MS/MS. In the case of the species of G_M1b which has a m/z 1626, the parent ion [CerO]^- at m/z 646.6 was used to produce secondary fragmentation S and T ions. The presence of an S ion at m/z 390 and a T ion at m/z 406 indicates that the long chain base is d18:1 and the fatty acid is C24:1. Therefore, the ceramide structure of this molecule was d18:1-C24:1 (Fig. 2). With this same approach, the ceramide structure of the second molecular species of G_M1b was identified. Thus, the analysis revealed that the G_M1b ganglioside had two ceramide structures, d18-1-C16:0 and d18:1-C24:1 (Table I) and led to the conclusion that two molecular species of G_M1b differing in their ceramide structures, are the major gangliosides of FBL-3 tumor cells. This latter finding is consistent with the general concept, shown in a number of other studies, that tumor-derived gangliosides frequently express heterogeneous ceramide structures (28, 33–35).

FBL-3 cells shed gangliosides

Significant shedding of gangliosides by tumor cells into the cellular microenvironment is thought to be a critical element in satisfying the hypothesis that tumor gangliosides interfere with the antitumor immune response, because to interact with host leukocytes, these molecules should be released by the tumor cells. We quantitated ganglioside shedding by the FBL-3 tumor cells and found that ~17% of cellular gangliosides were shed into the microenvironment in a 24-h period. This translates into a shedding rate of 90 pmol/10^6 cells/h, indicating that FBL-3 tumor cells shed gangliosides at a substantial rate. Qualitative analysis of the shed gangliosides by TLC/autoradiography revealed that G_M1b is both the major cellular and the major shed ganglioside (Fig. 3). This is consistent with previous observations and with the generally accepted concept that the major ganglioside species present on the

---

**Table I. Structural characterization of molecular species of FBL-3 cell gangliosides**

<table>
<thead>
<tr>
<th>Ganglioside</th>
<th>Molecular Ion</th>
<th>Fragment Ion</th>
</tr>
</thead>
<tbody>
<tr>
<td>G_M1b</td>
<td>d18:1-C16:0</td>
<td>1516</td>
</tr>
<tr>
<td></td>
<td>d18:1-C24:1</td>
<td>1626</td>
</tr>
</tbody>
</table>

The fragmentation pattern (molecular ion and fragment ions) identifies the gangliosides as d18:1-C16:0 G_M1b and d18:1-C24:1 G_M1b, as confirmed by FAB CAD-MS/MS.
cell membrane are also the species most prominent as shed molecules in the cell culture supernatant (8, 12, 28).

**FBL-3 gangliosides suppress the in vitro secondary proliferative response to syngeneic tumor cell challenge**

As a first step in determining the effects of tumor-derived gangliosides on the antitumor immune response, the effect of FBL-3 gangliosides on the secondary proliferative response of splenocytes to syngeneic tumor cells was examined. In these experiments, splenocytes from preimmunized mice were cultured in the presence or absence of FBL-3 gangliosides and restimulated with irradiated FBL-3 tumor cells. Ganglioside concentrations as low as 5 μM caused an 80% decrease in the proliferative response, in comparison with the secondary proliferative response of control splenocytes cultured in the absence of added gangliosides. Splenocytes exposed to 20 μM gangliosides showed almost 100% inhibition of proliferation (Fig. 4A). These results demonstrate that tumor-derived gangliosides can inhibit the tumor-specific secondary proliferative response.

The possibility that gangliosides could inhibit the immune response by merely altering the kinetics of the response was examined. [3H]Thymidine incorporation of ganglioside-exposed and control splenocytes from preimmunized mice was assessed at times before and after the maximal control response was observed (days 3–7). In this experiment, the maximal control response was observed on day 4 (Fig. 4B); whereas in the presence of 20 μM FBL-3 gangliosides, the proliferative response never achieved a level greater than 15% of the control response on any day. Thus, the addition of tumor-derived gangliosides completely inhibited the proliferative response without altering the kinetics of the response.

We excluded the possibility that the immunosuppressive activity of the FBL-3 gangliosides was the result of a nonspecific direct cytotoxic effect on the splenocytes. We exposed splenocytes from preimmunized mice to FBL-3 gangliosides for 4 days and then determined the viable cell counts. The cell counts of splenocytes incubated in 20 μM FBL-3 gangliosides were nearly equal to those of control cells (2.28 and 2.40 × 10^6/ml, respectively, representing a cell recovery of 57 and 60% of the initial 4 × 10^6 cells/ml plated). Therefore, the inhibition of the proliferative response caused by exposure of splenocytes to FBL-3 gangliosides was not the result of a direct effect on cell viability. Further supporting this conclusion is the fact that mitogen-induced lymphoproliferative responses are relatively unaffected even at ganglioside concentrations which cause marked inhibition of Ag-induced responses (36).

**FBL-3 gangliosides inhibit the generation of CTL specific for syngeneic FBL-3 tumor cells**

The ability of the immune system to develop T cells capable of recognizing and lysing specific tumor targets is critical for tumor elimination in vivo (37). To examine the effects of FBL-3 gangliosides on the CTL response, splenocytes (4 × 10^5/well) from preimmunized mice were cultured in the presence or absence (control) of 20 μM FBL-3 gangliosides and restimulated with 4 × 10^5 irradiated FBL-3 tumor cells. After 4 days of culture, the nonadherent cells were harvested and redirected against ^51Cr-labeled FBL-3 tumor targets at E:T ratios ranging from 100:1 to 3:1. A vigorous specific CTL response was observed; at an E:T ratio of 100:1, there was 72% specific lysis of FBL-3 targets and no significant lysis of the unrelated target, EL-4. FBL-3 gangliosides (20 μM) had a significant inhibitory effect on the CTL response, as shown in Fig. 5. At an E:T ratio of 100:1, for example, target cell
lysis was reduced by 97%. These results clearly show that FBL-3 gangliosides inhibit the generation of tumor-specific CTLs.

The effect of tumor gangliosides on the effector function of tumor-specific CTLs was also examined. In this case, splenocytes from preimmunized mice were stimulated with irradiated FBL-3 tumor cells for 4 days to allow generation and expansion of the tumor-specific CTL population. The CTLs were harvested and cytotoxicity directed against 51 Cr-labeled FBL-3 tumor targets in the presence or absence of 20 μM FBL-3 gangliosides was assessed in a standard chromium release assay. Lytic activity of the ganglioside-exposed splenocytes at an E:T ratio of 100:1 (59% lysis of tumor targets) was only slightly lower than the 72% lysis by splenocytes not exposed to gangliosides (Fig. 5). Thus, the inhibitory effect of the tumor gangliosides on the antitumor CTL response reflects a significant inhibitory effect on the generation phase combined with only a minimal effect on the effector phase of the response.

C57BL/6 mice develop a measurable and specific antitumor immune response to FBL-3 cells

The first step in the establishment of an in vivo tumor system in which the antitumor immune response could be measured was to develop a mouse model that is capable of recognizing and lysing the specific tumor cell, FBL-3. To accomplish this, C57BL/6 mice were immunized with FBL-3 tumor cells as described by Kern et al. (23). Two weeks after the second immunization, we determined whether or not the immunization was successful by injecting immunized as well as naive mice (i.e., not immunized with FBL-3 cells) with a live tumor cell challenge (5 \times 10^6 FBL-3 cells) and observing them for survival. All three of three immunized mice rejected the tumor challenge, whereas all naive mice rapidly developed tumors.

To determine whether an immune response to the FBL-3 tumor cells could be detected in vivo, we used a modified PLN assay (30, 31). Previously immunized mice were challenged in their left rear footpads with 2.5 \times 10^6 irradiated FBL-3 tumor cells or B78H1 tumor cells. Five days after the injection, the immune response was quantified by harvesting the stimulated draining PLNs and comparing their mass and cell number to those of unstimulated PLNs. FBL-3-stimulated lymph nodes showed an increase in mass of 1.9 mg and an increase in cell number of 1.7 \times 10^6/node, compared with unstimulated lymph nodes, demonstrating that there was a
vigorouand quantifiable immune response to the syngeneic FBL-3 tumor cells. In contrast, mice preimmunized with irradiated FBL-3 and challenged with unrelated tumor cells (B78Hl) did not produce a significant response (0.3 ± 0.2 mg increase in mass and no detectable increase in cell number), demonstrating that the immune response was specific for the FBL-3 tumor cells. These results confirm previous studies (38) showing that C57BL/6 mice immunized with FBL-3 cells can develop an effective and specific immune response to an FBL-3 tumor challenge and demonstrate that this model can be used to directly measure the effects of tumor gangliosides on the antitumor immune response to syngeneic tumor cells.

FBL-3 tumor gangliosides inhibit the in vivo primary antitumor immune response to FBL-3 tumor cells

The primary immune response to a tumor challenge most closely mirrors the likely initial interaction between the tumor cell and the immune system. Unsuccessful attempts to directly assess this response suggest that the FBL-3 tumor cells are not sufficiently immunogenic to produce a measurable primary immune response in the PLN assay. Therefore, to measure the effects of tumor gangliosides on the primary antitumor immune response in vivo, 10 nmol of FBL-3 gangliosides were coinjected with the primary FBL-3 tumor cells. These results confirm previous studies (38) showing that C57BL/6 mice immunized with FBL-3 cells can develop an effective and specific immune response to an FBL-3 tumor challenge and demonstrate that this model can be used to directly measure the effects of tumor gangliosides on the antitumor immune response to syngeneic tumor cells.

FBL-3 tumor gangliosides inhibit the increase in lymph node mass in response to secondary syngeneic tumor cell challenge in vivo

In addition to examining the effects of tumor gangliosides on the primary antitumor immune response, using the same assay system, the modified PLN assay, we quantified the effects of FBL-3 gangliosides on the in vivo secondary antitumor immune response. The first parameter measured was the increase in PLN mass in response to syngeneic FBL-3 tumor cell challenge. When previously immunized mice were stimulated with FBL-3 tumor cells admixed with FBL-3 gangliosides (10 nmol), there was a marked reduction in the increase in PLN mass. Whereas the mean increase in lymph node mass in mice stimulated with FBL-3 tumor cells was 1.85 mg, the coinjection of purified FBL-3 gangliosides with FBL-3 tumor cells resulted in only a 0.72-mg increase in lymph node mass. This 61% inhibition of the response demonstrates that FBL-3 gangliosides significantly (p ≤ 0.02) suppress the increase in lymph node mass caused by syngeneic tumor challenge in vivo (Fig. 7A), and in fact to a degree similar to that caused by treatment of mice with cyclosporin (24 mg/kg i.p. daily for 4 days), a standard system for suppression of the cellular immune response (32).

FBL-3 gangliosides inhibit the secondary lymphoproliferative response in vivo

The effect of FBL-3 gangliosides on the in vivo secondary lymphoproliferative response to syngeneic tumor challenge was directly examined in two ways: by determination of the increase in PLN cell number; and by quantification of the spontaneous proliferative response. Unstimulated lymph nodes contained 0.19 × 10⁶ cells/node. Lymph nodes stimulated with γ-irradiated FBL-3 cells contained 1.83 × 10⁶ cells/node, which represents an almost 10-fold increase in cell number. However, when the FBL-3 cell challenge was injected together with FBL-3 gangliosides, the draining lymph nodes harvested 5 days later contained only 0.73 × 10⁶ cells, indicating a marked inhibition by gangliosides of the increase in cell number (Fig. 7B). FBL-3 gangliosides also significantly (p = 0.006) reduced the spontaneous proliferative response, as measured by [³H]thymidine uptake, by 41%, from
Once again these results indicated a similar effect to that achieved by the repeated injection of cyclosporin (Fig. 7, B and C). These in vivo studies provide strong evidence that FBL-3 gangliosides significantly suppress the antitumor immune response in vivo.

**FBL-3 gangliosides inhibit the tumor-induced activation and expansion of lymph node cell populations in vivo**

Changes in the PLN populations induced by gangliosides were further delineated by determining the expression of cell surface markers specific for cell lineage and activation status. Lymph node cells from mice injected in the footpad with irradiated FBL-3 cells admixed with FBL-3 gangliosides (10 nmol) or injected with irradiated FBL-3 cells alone (control) were stained with fluorescence-conjugated mAbs for lineage-specific markers including CD3 (T cells), CD4 (Th cell), CD8 (CTL), CD19 (B cells), and Mac-3 (dendritic cells/macrophage) as well as activation markers CD69 (early activation marker), and CD25 (IL-2 receptor) and analyzed by FACS. This allowed us to determine changes in both the total number and activation status of cells from the various cell populations involved in the antitumor immune response in vivo. Comparing the cell populations of lymph nodes draining the site of FBL-3 cell injection with the cell populations of unstimulated lymph nodes, it was apparent that s.c. injection of the FBL-3 cells caused a significant increase in all cell populations examined (Fig. 8A). This increase was suppressed in the lymph nodes of mice also receiving the FBL-3 gangliosides. For example, the T cell population (CD3) increased from $2.2 \times 10^5$ cells/node in the unstimulated lymph node to $11.1 \times 10^5$ cells/node in the stimulated, control lymph nodes, but to only $5.5 \times 10^5$ cells/node in the stimulated lymph nodes of ganglioside-treated mice (63% decrease). These ganglioside-induced changes were evident in the T cell subpopulations, in which there was 57 and 65% inhibition of the CTL and T helper cell populations, as well as in the B cell and dendritic cell/macrophage populations, which were decreased by 74 and 69%, respectively. The expression of activation markers was also affected; coinjection of FBL-3 tumor gangliosides with FBL-3 cells led to a significantly reduced number of lymph node cells expressing CD69 and CD25 (60 and 71%, respectively). Overall, ganglioside-induced inhibition of each lymph node cell subpopulation studied was statistically significant ($p \leq 0.04$), whereas the distribution of the cell populations showed that the inhibition was not specific for any single population examined.
Discussed was the in vivo administration of the tumor gangliosides and the suppressor activity of the observed increase of cell populations associated with the antitumor immune response in vivo.

Discussion

The hypothesis that gangliosides shed by tumors bind to host leukocytes and suppress the antitumor immune response is supported by a number of observations. It has been shown that tumor cells synthesize and shed gangliosides (5, 8–12) and that these shed molecules directly bind to target cells in vitro (39, 40). Other work has demonstrated the immunosuppressive activity of gangliosides. Gangliosides inhibit the in vitro proliferative response of lymphocytes to both nonspecific mitogens (16–18) and soluble Ags (e.g., tetanus toxoid) (8, 41) and have been shown to be inhibitors of the cytotoxic response in vitro (20–22). Initial in vivo studies demonstrated that gangliosides are highly effective in suppressing the allogeneic immune response (31, 42), providing one possible explanation for the earlier observation that addition of gangliosides to poorly tumorigenic cells significantly increased their tumorigenic potential in vivo (29). Together, these findings all point to a possible role of gangliosides in modulating the ability of tumor cells to escape host immune destruction. However, before the present work, there has been no direct evidence, either in vitro or in vivo, of inhibition of the specific antitumor immune response by tumor-derived gangliosides.

The present study has taken advantage of the well-documented antitumor immune response developed in the FBL-3 tumor model, allowing us to comprehensively examine the impact of tumor gangliosides on the antitumor immune response. Here we directly tested the hypothesis that tumor cells actively shed biologically active gangliosides into their microenvironment, where they serve as a protective barrier, binding to host lymphocytes and preventing them from developing an efficient antitumor immune response. We found that FBL-3 tumor cells shed gangliosides at a high rate, creating a tumor microenvironment rich in tumor-derived gangliosides. Using the highly purified FBL-3 gangliosides, we showed in vitro inhibition of the tumor-specific secondary proliferative response and of the generation of tumor-specific CTLs. In vivo, we observed inhibition of both the primary and secondary antitumor immune responses. These studies provide the first direct evidence that tumor gangliosides are highly effective inhibitors of the syngeneic antitumor immune response and thereby establish tumor cell ganglioside metabolism as an active factor in the process of tumor formation.

Immunosuppressive activity is a general biological property of gangliosides that is not specifically limited by the source of the gangliosides but that is influenced by their molecular structure. In fact, gangliosides other than the disialoganglioside G_{M3} studied here, such as those isolated from LAN-5 neuroblastoma cells (which are mainly G_{D2} and G_{M2}) (43), also are effective inhibitors of the immune response to FBL-3 tumor cells (unpublished data). Variations in either the carbohydrate or the ceramide structure can lead to differing degrees of activity. For example, in comparing a series of highly purified normal human brain gangliosides, those with a terminal sialic acid linked to a compact neutral oligosaccharide had the greatest immunosuppressive activity (36). Other studies examining the relationship between structure and activity revealed that tumor gangliosides were frequently more immunosuppressive than corresponding normal human brain gangliosides of identical carbohydrate structure. These differences were inversely related to the length of the ceramide fatty acyl chain (34). Thus, immunosuppressive activity is quantitatively affected by ganglioside structure.

Another factor influencing activity is presence of these molecules in the tumor microenvironment. Because tumor cells shed gangliosides at a high rate, it was predicted that the concentration of gangliosides in the tumor microenvironment would be very high. This was supported by recent findings in an in vitro system in which the shedding rate and microenvironmental ganglioside concentrations could be estimated (39, 40). Therefore, in contrast to lower concentrations in the peripheral circulation, the tumor cell microenvironment may contain high concentrations of highly active gangliosides, leading to maximal inhibition of the antitumor immune response at the site of tumor formation and progression.

The mechanisms of ganglioside-induced immunosuppression are most likely multiple and remain to be fully elucidated. However, it is clear that both APC and T cells are affected by tumor gangliosides. Some of the known mechanisms are reversible inhibition of APC function (13, 14), inhibition of IL-2-induced T cell proliferation (44), and down-regulation of CD4 expression (45–47). Most recently, it has been shown that exposure of mouse splenocytes to gangliosides results in reduced gene transcription of the Th1-associated cytokines, IL-2 and IFN-γ, while leaving gene transcription of the Th2-associated cytokines, IL-4 and IL-10, unaffected (48). Others have reported a ganglioside-induced increase in T cell IL-10 production (49). Together, these findings suggest that shed tumor gangliosides may shift the balance of the antitumor immune response from the normally predominant Th1 response toward the Th2 response, possibly leading to a reduction in the cellular antitumor immune response critical for tumor elimination. Because the earliest stage of the cellular immune response known to be affected by exposure to gangliosides is Ag presentation (13, 14), it is tempting to speculate that the initial step in tumor ganglioside-induced immunosuppression in vivo is interference with the functions of APC, which in the FBL-3 tumor model would predominantly be dendritic cells.

Notwithstanding gaps in knowledge regarding the mechanism of immunosuppression by tumor gangliosides, the conclusion supported by the present work, that gangliosides shed by tumor cells can suppress the ability of the immune system to recognize and eliminate tumor cells, may have direct relevance to human cancer. Corroborating evidence includes the observations that aggressive neuroblastomas shed significant quantities of gangliosides in vivo and that the level of shed gangliosides was directly related to the incidence of tumor recurrence and the rapidity of progression (50). It has been proposed that clinically it may be possible to boost the immune response, specifically or nonspecifically, to enhance tumor cell recognition and elimination (51–53). However, to date such attempts have had only limited success. This may stem in part from the ability of tumor cells to escape immune recognition by various mechanisms, one being the shedding of tumor gangliosides into the microenvironment. Thus, a potentially therapeutic enhancement of the immune response could be negated by the particular immunosuppressive activity of the tumor. Approaches designed to inhibit such tumor cell escape mechanisms would be desirable. Recently, it was shown that metabolic depletion of tumor gangliosides is possible by treating cells with inhibitors of the synthesis of glucosylceramide, a metabolic precursor of gangliosides (40, 43, 54, 55). With the recognition of a causative role of gangliosides in tumor-associated immunosuppression and a facilitative role in tumor progression, the use of such inhibitors of ganglioside synthesis might enhance the effectiveness of immunotherapeutic approaches to cancer.
Acknowledgments

We thank Dr. Phillip Greenberg for providing the FBL-3 cell line, Dr. Hyam Levitsky for providing the B78H1 cell line, Dr. Douglas Gage for performing the mass spectrometric analysis of the FBL-3 tumor gangliosides, and Barbara Taylor for her assistance with the flow cytometric analysis.

References

1. Burnet, F. M. 1970. The concept of immunological surveillance. Prog. Exp. Tu-
   mor Res. 13:1.
2. Bocchia, M., T. Korontziv, Q. Xu, S. Mackinnon, S. Y. Yang, A. Sette, and 
   D. A. Scheinberg. 1996. Specific human cellular immunity to bcr-abl onco-
3. Cheever, M. A., M. L. Disis, H. Bernhard, J. R. Gralow, S. L. Hand, 
   E. S. Huseby, H. L. Qin, M. Takahashi, and W. Chen. 1995. Immunity to onco-
4. Boon, T., and F. van der Bruggen. 1996. Human tumor antigens recognized by T 
   melanoma cells: examination of its role in immunosuppression mediated by 
7. Tada, T., S. Ohzeki, K. Usumi, T. Kachi, M. Muramatsu, X. F. Li, J. Shimizu, 
   H. Fujitaka, and T. Hamaoka. 1991. Transforming growth factor-β-induced in-
   hibition of T cell function: susceptibility difference in T cells of various pheno-
   types and functions and its relevance to immunosuppression in the tumor-bearing 
   osides in blood serum of normal rats and Morris hepatoma 512tc-bearing rats. 
    264:12097.
11. Ladisch, S., R. Li, and E. Olsson. 1994. Ceramide structure predicts tumor gan-
    gliosides. I. Relationship of carbohydrate structure to the inhibition of T cell 
    histocompatibility complex class I antigens in tumor growth and metastasis. 
    ubilized TSTA and the membrane structural proteins gp70 and p30, in the 
    immune response to murine leukemias induced by Friend and Rauscher virus. 
    Int. J. Cancer 20:93.
    gangliosides. FZBS Lett. 886:11.
    fer of human medulloblastoma gangliosides: abrasion by a new inhibitor of 
    and in vivo immunosuppressive activity of neuroblastoma G D2. Glycoconj. 
20. Li, R., and S. Ladisch. 1996. Abrogation of shedding of immunosuppressive neuroblas-
    toma gangliosides. Cancer Res. 56:4602.
    1094:35.
22. Oflner, H., T. Thierne, and A. A. Vandenbark. 1987. Gangliosides induce selec-
23. Garofalo, T., M. Sorice, R. Misasi, B. Cinque, M. Giampietro, M. G. Pontieri, 
    induced by ganglioside GM 2: involvement of serine phosphorylation and 
24. Kresulis, O., L. D. Bergelson, and M. Schlesinger. 1998. The down-modulation of 
    CD4 induced by the G M1 ganglioside is regulated by phosphatases and kinases: 
    187:17.
    T cell line. J. Neuroimmunol. 87:11.
    8:357.
    25:661.
    Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthase, on ex-
   pression of cell surface glycolipid antigen and binding to adhesive proteins by 
    T cell line. J. Neuroimmunol. 87:11.
    gangliosides. I. Characteristics of inhibitory effects and the induction of impaired 
    of melanoma cells: examination of its role in immunosuppression mediated by 